Article Information
PubMed
Published By
Online ISSN
History
- Received September 16, 2021
- Revision received May 4, 2022
- Accepted May 5, 2022
- Published online May 17, 2022.
Copyright & Usage
© 2022 Gutierrez-Prat et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Author Information
- Nuria Gutierrez-Prat1,
- Hedwig L Zuberer1,
- Luca Mangano1,
- Zahra Karimaddini2,
- Luise Wolf2,
- Stefka Tyanova2,
- Lisa C Wellinger4,
- Daniel Marbach3,
- Vera Griesser3,
- Piergiorgio Pettazzoni1,
- James R Bischoff1,
- Daniel Rohle4,*⇑,
- Chiara Palladino1,*⇑ and
- Igor Vivanco5,*⇑
- 1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
- 2Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, Basel, Switzerland
- 3Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland
- 4Ridgeline Discovery Basel, Basel, Switzerland
- 5Institute of Pharmaceutical Science, King’s College London, London, UK
- Correspondence: igor.vivanco@kcl.ac.uk; chiara.palladino@roche.com; dan@charmtx.com
↵* Daniel Rohle, Chiara Palladino, and Igor Vivanco contributed equally to this work.
Funding
Roche Postdoctoral Fellowship Program
N Gutierrez-Prat
DUSP4 restricts MAPK overdose in melanoma
In this Issue
Advertisement
Subjects
Related Articles
Cited By...
- No citing articles found.